A Phase 1/2 interventional study of 8-Chloroadenosine and Laboratory Biomarker Analysis in Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, sponsored by City of Hope Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by City of Hope Medical Center · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center — 15 open to participants now, 32 under way, none of them phase 3. Leukemia, Myeloid, Acute · City of Hope Medical Center.
Among the 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center, this one is the 34th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2015, is one of 4 in phase 1/2, and was the 25th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →15 of the 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18–75
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 20
First in 1994; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 30 across the 57 interventional studies, 107 across the 6 observational. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
17 of the studies in Leukemia, Myeloid, Acute by City of Hope Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06059391City of Hope Medical CenterCMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | 2027-01-01 |
| NCT03728335City of Hope Medical CenterEnasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation | 2027-01-11 |
| NCT06763341City of Hope Medical CenterA Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | 2027-01-16 |
| NCT06543381City of Hope Medical CenterOlutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | 2027-02-05 |
| NCT05222984City of Hope Medical CenterNavitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | 2027-03-02 |
Add all 17 to your calendar (.ics) → With an account.
Among the 63 studies in Leukemia, Myeloid, Acute by City of Hope Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase I/II trial studies the side effects and best dose of 8-chloroadenosine and to see how well it works in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as 8-chloroadenosine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (recommended phase II dose, RP2D) of 8-chloro-adenosine, when given as a single agent, in patients with relapsed or refractory acute myeloid leukemia. (Phase I) II. To assess tolerability and safety of 8-chloro-adenosine at each dose level by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration. (Phase I) III. To estimate the response rate and to evaluate the antitumor activity of 8-chloro-adenosine, when given as a single agent, as assessed by complete remission rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]). (Phase II)
SECONDARY OBJECTIVES:
I. To evaluate for disease response to 8-chloro-adenosine in refractory/relapsed acute myeloid leukemia (AML) on each dose level tested. (Phase I) II. To obtain estimates of remission duration and survival probabilities (overall and event-free). (Phase II) III. To obtain an estimate of the overall response rate (CR + CRi + partial response [PR]). (Phase II) IV. To summarize and evaluate toxicities by type, frequency, severity, attribution, time course and duration. (Phase II)
CLINICAL PHARMACOLOGY OBJECTIVES:
I. To describe the plasma, urinary and cellular pharmacokinetics of 8-chloro-adenosine and metabolites.
II. To determine the impact of 8-chloro-adenosine on cellular adenosine triphosphate (ATP) pool in AML blasts.
III. To assess the impact of 8-chloro-adenosine therapy on select short-lived messenger (m) ribonucleic acids (RNAs) and corresponding proteins in circulating AML blasts.
IV. To correlate clinical responses and toxicity with plasma/urine 8-chloro-adenosine level (pharmacokinetic [PK]), cellular 8-chloro-ATP (PK) and cellular ATP pool.
EXPLORATORY EX-VIVO MOLECULAR OBJECTIVES:
I. To determine the cytotoxicity of 8-chloro-adenosine toward leukemic progenitor cells in vitro.
II. To generate a preliminary pre-treatment RNA/micro RNA (miRNA) signature in leukemic progenitor cells, and explore its possible association with in vitro cytotoxicity to 8-chloro-adenosine.
III. To explore the possible association between the preliminary RNA/miRNA signature and clinical response to 8-chloro-adenosine.
OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.
Patients receive 8-chloro-adenosine intravenously (IV) over 4 hours on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet one of the three treatment history criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study
200mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study
400mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study
800mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study
400mg/m\^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study
600mg/m\^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
Drug: 8-Chloroadenosine · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study
Given IV
Also known as: 8-Chloro-adenosine, 8-Cl-adenosine, 8-Cl-Ado
Correlative studies
Correlative studies
Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado)
According to the standard 3+3 rules, where the highest DL that produced ≤ 1/6 DLTs in cycle 1 would be defined as the maximum tolerated dose (MTD). The RP2D of 8-Cl-Ado would generally be the MTD, but it could be less than the initially calculated MTD as determined from a review of the available data and cumulative toxicities from phase 1.
Time frame: Up to 28 days following first study agent administration.
Dose Limiting Toxicity (DLT)
Toxicity was graded according to the NCI-Common Terminology Criteria for Adverse Events version 4.03. A DLT was defined as any of the following toxicities (please see the details in section of 13.2 of the protocol) that occur during cycle 1, per CTCAE version 4.03, and were considered related to the study drug.
Time frame: Up to 28 days following first study agent administration.
Complete Remission Rate (CR + CRi)
Complete remission rate (CR + CRi) based on the Döhner 2010 criteria and calculated as the percent of evaluable patients that have confirmed CR or CRi is to evaluate the antitumor activity of 8-chloro-adenosine.
Time frame: Up to 2 years following first study agent administration.
| Milestone | Phase I - 100mg/m^2 1-hour Infusion | Phase I - 200mg/m^2 1-hour Infusion | Phase I - 400mg/m^2 1-hour Infusion | Phase I - 800mg/m^2 1-hour Infusion | Phase I - 400mg/m^2 4-hour Infusion | Phase I - 600mg/m^2 4-hour Infusion |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 2 | 2 | 6 |
| Completed | 3 | 3 | 4 | 2 | 2 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
According to the standard 3+3 rules, where the highest DL that produced ≤ 1/6 DLTs in cycle 1 would be defined as the maximum tolerated dose (MTD). The RP2D of 8-Cl-Ado would generally be the MTD, but it could be less than the initially calculated MTD as determined from a review of the available data and cumulative toxicities from phase 1.
| mg/m^2 | Phase I - Treatment (8-chloro-adenosine) |
|---|---|
| Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado) | 400 |
Toxicity was graded according to the NCI-Common Terminology Criteria for Adverse Events version 4.03. A DLT was defined as any of the following toxicities (please see the details in section of 13.2 of the protocol) that occur during cycle 1, per CTCAE version 4.03, and were considered related to the study drug.
| Participants | Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion | Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion |
|---|---|---|---|---|---|---|
| Dose Limiting Toxicity (DLT) | 0 | 0 | 1 | 2 | 0 | 2 |
Complete remission rate (CR + CRi) based on the Döhner 2010 criteria and calculated as the percent of evaluable patients that have confirmed CR or CRi is to evaluate the antitumor activity of 8-chloro-adenosine.
| Percent of evaluable patients | Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion | Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion |
|---|---|---|---|---|---|---|
| Complete Remission Rate (CR + CRi) | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Up to 2 years following first study agent administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion | 4/4 (100%) | 2/4 (50%) | 4/4 (100%) |
| Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion | 6/6 (100%) | 6/6 (100%) | 6/6 (100%) |
| Event | Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion | Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion |
|---|---|---|---|---|---|---|
| CARDIAC ARRESTCardiac disorders | 0/3 | 0/3 | 1/4 | 1/2 | 0/2 | 0/6 |
| MULTIORGAN FAILUREGeneral disorders and administration site conditions | 0/3 | 0/3 | 0/4 | 0/2 | 1/2 | 1/6 |
| SEPSISInfections and infestations | 0/3 | 0/3 | 0/4 | 1/2 | 0/2 | 1/6 |
| DISEASE PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/3 | 0/4 | 0/2 | 1/2 | 0/6 |
| INVASIVE PULMONARY ASPERGILLOSISRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/4 | 1/2 | 0/2 | 0/6 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/3 | 0/3 | 0/4 | 0/2 | 0/2 | 2/6 |
| PNEUMONIARespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/4 | 0/2 | 0/2 | 0/6 |
| LUNG INFECTIONInfections and infestations | 0/3 | 0/3 | 1/4 | 0/2 | 0/2 | 0/6 |
| LEUKEMIANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 1/4 | 0/2 | 0/2 | 0/6 |
| SUPRAVENTRICULAR TACHYCARDIACardiac disorders | 0/3 | 0/3 | 0/4 | 0/2 | 0/2 | 1/6 |
| Event | Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion | Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion |
|---|---|---|---|---|---|---|
| ANEMIABlood and lymphatic system disorders | 3/3 | 3/3 | 3/4 | 1/2 | 2/2 | 6/6 |
| SINUS TACHYCARDIACardiac disorders | 1/3 | 3/3 | 3/4 | 1/2 | 0/2 | 6/6 |
| VENTRICULAR TACHYCARDIACardiac disorders | 0/3 | 0/3 | 0/4 | 0/2 | 2/2 | 0/6 |
| DIARRHEAGastrointestinal disorders | 2/3 | 3/3 | 2/4 | 0/2 | 0/2 | 3/6 |
| NAUSEAGastrointestinal disorders | 1/3 | 2/3 | 3/4 | 2/2 | 1/2 | 4/6 |
| FATIGUEGeneral disorders and administration site conditions | 1/3 | 1/3 | 2/4 | 1/2 | 2/2 | 4/6 |
| FEVERGeneral disorders and administration site conditions | 0/3 | 1/3 | 4/4 | 2/2 | 0/2 | 3/6 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 0/3 | 1/3 | 0/4 | 2/2 | 0/2 | 3/6 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 1/3 | 0/3 | 0/4 | 2/2 | 0/2 | 4/6 |
| BLOOD BILIRUBIN INCREASEDInvestigations | 3/3 | 3/3 | 2/4 | 2/2 | 2/2 | 6/6 |
| Age, Continuous(years) | Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion | Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion | Total |
|---|---|---|---|---|---|---|---|
| Median | 75 (69 to 77) | 54 (28 to 66) | 59 (45 to 71) | 56 (50 to 63) | 68 (59 to 77) | 70 (61 to 75) | 66 (28 to 77) |
| Sex: Female, Male(Participants) | Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion | Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 3 | 2 | 1 | 4 | 12 |
| Male | 2 | 2 | 1 | 0 | 1 | 2 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion | Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 1 | 1 | 0 | 3 | 7 |
| Not Hispanic or Latino | 3 | 1 | 3 | 1 | 2 | 3 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Phase I - 100mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 200mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 800mg/m^2 8-chloro-adenosine 1-hour Infusion | Phase I - 400mg/m^2 8-chloro-adenosine 4-hour Infusion | Phase I - 600mg/m^2 8-chloro-adenosine 4-hour Infusion | Total |
|---|---|---|---|---|---|---|---|
| United States | 3 | 3 | 4 | 2 | 2 | 6 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Mar 2021, 65 months.
Results were first posted in Dec 2023, 2 years 8 months after primary completion.
Of 134 non-industry phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 110. This study's 65 months is below that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
Start moved once since we started tracking on Sep 25, 2026: Sep 2015 → Oct 2015, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 8-chloroadenosine